启明创投

@author-1788515151757110

224 articles

Articles

Qiming Star | Tianchen Biotech Raises Over 200 Million Yuan in Series C, Co-Led by Qiming Venture Partners

Qiming Star | Tianchen Biotech Raises Over 200 Million Yuan in Series C, Co-Led by Qiming Venture Partners

TianChen Bio is committed to setting the industry benchmark in allergic diseases and complement-mediated diseases, continuously driving treatment innovation to deliver breakthrough therapies with greater clinical value and accessibility for patients worldwide.

Qiming ESG | Qiming Venture Partners Rural Revitalization Entrepreneur Support Program Holds 2025 Industry Entrepreneur Quality Development Exchange in Chengdu

Qiming ESG | Qiming Venture Partners Rural Revitalization Entrepreneur Support Program Holds 2025 Industry Entrepreneur Quality Development Exchange in Chengdu

The "Rural Revitalization Entrepreneurship Support Program" was jointly launched by Qiming Venture Partners and the China Foundation for Rural Development. It aims to leverage the respective resource advantages of both organizations in venture capital and philanthropy to provide sustained support for rural entrepreneurs.

Qiming Venture Partners Backs Three Honorees on MIT Technology Review's 2024 Innovators Under 35 China List

Qiming Venture Partners Backs Three Honorees on MIT Technology Review's 2024 Innovators Under 35 China List

After eight years, the "35 Innovators Under 35" selection has evolved into a distinctive innovation ecosystem whose diversity has injected unique vitality into China's technological development — particularly in AI, where the results have been especially striking.

Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident

Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident

In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.

Qiming Venture Partners' Duane Kuang: China's new quality productive forces are going global, and the venture capital industry can play an important role

Qiming Venture Partners' Duane Kuang: China's new quality productive forces are going global, and the venture capital industry can play an important role

Venture capital firms' tolerance for high risk and focus on long-term value inherently make them adventurous, willing to back technological innovation. By building a closed innovation loop that moves from "blood transfusion" to "blood creation," they can deeply embed themselves in company growth. And they have the ability to identify the most promising entrepreneurs and the most compelling directions for innovation.

Morning Star | Four Qiming Venture Partners Portfolio Companies Selected for S&P Global Sustainability Yearbook (China Edition) 2025

Morning Star | Four Qiming Venture Partners Portfolio Companies Selected for S&P Global Sustainability Yearbook (China Edition) 2025

The Yearbook aims to identify and recognize Chinese companies that have demonstrated sustainable development advantages in industries such as biotechnology, healthcare, machinery and electrical equipment, automotive manufacturing, and communications equipment.